Chinook Therapeutics (NASDAQ:KDNY) released its quarterly earnings results on Tuesday. The company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.82), MarketWatch Earnings reports. Chinook Therapeutics had a negative net margin of 215.80% and a negative return on equity of 112.72%.
Shares of Chinook Therapeutics stock opened at $14.75 on Thursday. The firm has a market capitalization of $621.83 million, a P/E ratio of -4.10 and a beta of 0.26. Chinook Therapeutics has a 12-month low of $10.50 and a 12-month high of $21.68. The business’s 50-day moving average price is $16.88.
Several equities analysts recently commented on KDNY shares. Cantor Fitzgerald started coverage on shares of Chinook Therapeutics in a research note on Wednesday, December 9th. They issued an “overweight” rating and a $31.00 price target on the stock. Bloom Burton restated a “buy” rating on shares of Chinook Therapeutics in a research note on Monday, March 22nd. Wedbush started coverage on shares of Chinook Therapeutics in a research note on Wednesday, January 6th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 11th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $28.29.
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.